News 13.10.2022 SAN DIEGO – October 11, 2022 – aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has entered into a research collaboration with Dualsystems Biotech AG, a company...
News 11.10.2022 Schlieren (Zurich), Switzerland, 11 October, 2022 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it will present compelling clinical data on MagnetOs bone graft at the 38th Annual Meeting of the North American Spine Society (NASS), being held in Chicago October...
News 03.10.2022 Schlieren (Zurich), Switzerland, October 3, 2022 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it has appointed Chris Fair as Chief Operating Officer (COO). Mr. Fair is a leader in the musculoskeletal and regenerative medicine industry with more than 25...
News 15.09.2022 Schlieren (Zurich), Switzerland, September 15, 2022 – Kuros Biosciences AG (SIX:KURN) a leader in next generation bone graft technologies, announced today the successful completion of a CHF 6.0 million capital increase through a private placement of 3,750,000 new shares of Kuros with a par value of CHF 0.10 each (the...
News 08.09.2022 Zurich-Schlieren, Switzerland, September 08, 2022. Proteomedix, a Swiss diagnostics company committed to advance prostate cancer care, announces grant of patent in China for Proclarix®. The China National Intellectual Property Administration notified Proteomedix of the grant of the patent for the invention described in the application No. 201780043349.5, titled “Method of detecting proteins in...